Mirvie is dedicated to shaping the future of pregnancy health
Mirvie is shaping the future of pregnancy health by providing women and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.
The Future of Pregnancy Health Starts Here
One in five pregnancies is impacted by complications.
The Mirvie RNA platform has the power to predict them before they happen123 enabling proactive, preventive, and personalized pregnancy care for the well-being of millions of moms and babies.
The idea for Mirvie was sparked by the personal experience of one of the founders whose daughter was born prematurely.
Mirvie’s world-class team of scientists and entrepreneurs.
Mirvie’s team members have brought to market category-first, non-invasive tests in both women’s health and in early cancer detection, used by millions today.
Alison Cowan, M.D.
Head of Medical Affairs
Michal Elovitz, M.D.
Chief Medical Advisor
Hong Frank
Head of Software Engineering
Carrie Haverty
Head of Product Management
Maneesh Jain
Chief Executive Officer & Co-Founder
Naomi Kelman
Board Member
Karen Kirk
Vice President of Finance & Administration
Stanley Lapidus
Board Chair
Manfred Lee
Chief Operating Officer
Alison Moe
Head of Clinical Operations
Eugeni Namsaraev
Senior Vice President of Research & Development
Stephen Quake
Scientific Advisory Board Chair & Co-Founder
Morten Rasmussen
Head of Research
Mirvie has raised more than $90 million in early-stage financing from top-tier investors.
Funds and Accounts managed by
INVESTORS
Interested in helping us shape the future of pregnancy health?
